Activation syndrome

Activation syndrome is a form of stimulation (sometimes suicidal) or agitation that has been observed in association with some psychoactive drugs.[1] A causative role has not been established.[2] Pfizer has denied that sertraline can cause such effects.[3][4]

Treatment

Serotonin reuptake inhibitors (SSRI) have been associated with a state of restlessness, lability, agitation, and anxiety termed "activation syndrome". In some people, this state change can increase suicidal tendencies, especially in those under age 25 and during the initial weeks of treatment.[5] SSRI-induced activation syndrome is well-accepted by clinicians.[6] Evidence reveal that jitteriness/anxiety syndrome predicts an improved prognosis (level D). Activation syndrome resolves within hours of discontinuing the serotonergic agent and initiating care. However, resolution of symptoms may be slightly longer in those taking medications with longer half-lives, such as monoamine oxidase inhibitors (MAOIs).

References

  1. ↑ http://www.breggin.com/recentregulatory.pbreggin.2006.pdf
  2. ↑ "www.accessdata.fda.gov" (PDF).
  3. ↑ http://www.healyprozac.com/AcademicStalking/Post%203%20-%20Pfizer%20letter%20re%20Healy.pdf
  4. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2010-12-23. Retrieved 2010-06-14.{{cite web}}: CS1 maint: archived copy as title (link)
  5. ↑ "www.accessdata.fda.gov" (PDF).
  6. ↑ Reid JM, Storch EA, Murphy TK, Bodzin D, Mutch PJ, Lehmkuhl H, Aman M, Goodman WK (2010). "Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile". Child Youth Care Forum. 39: 113–124. doi:10.1007/s10566-010-9095-5. PMC 2867356. PMID 20473344.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.